Telix (ASX:TLX) says olaratumab, an antibody licensed from Eli Lilly, has demonstrated proof-of-concept in a preclinical study investigating its delivery of diagnostic and therapeutic radiation to tumours. …
Telix says olaratumab antibody licensed from Lilly demonstrates proof of concept
April 17, 2023 Australian Biotech
Latest Video
New Stories
-
BPDInsights one week out with patient voices leading the agenda
May 11, 2026 - - Latest News -
It's mostly a mistake to read too much into a Budget forecast because of what it doesn't include
May 11, 2026 - - Latest News -
Budget silence on HTA Review would confirm what we already know - delayed rollout
May 9, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News